Business
Novo Bets Up to $1.4B on Making Peptide Drugs You Can Swallow
Injectable peptides rule the obesity market, but they’re hard to turn into pills. Novo’s new alliance with Orbis targets a class of ring-shaped molecules designed to survive the gut.